Abstract
12 women with primary breast cancer underwent somatostatin receptor scintigraphy (SRS) with 111In-DTPA-D-Phe1-octreotide. The tumour sizes varied between 2 and 5 cm and were all, except one, palpable at clinical examination. Tumour biopsies were taken with additional sampling from normal breast tissue, fat, muscle, axillary lymph nodes and peripheral blood. Ratios between the 111In activity concentration in the tissue biopsies (Ti) and in peripheral blood (B) as well as in normal breast tissue (Br) were calculated. In 8/12 patients the scintillation detector was used intraoperatively for radioactivity measurements of the biopsies in situ and ex vivo. The sstr-subtype profiles were determined by northern blot analysis and the relative expression of sstr2 by ribonuclease protection assay (RPA) and immunocytochemistry. Preoperative SRS visualised all primary breast cancer tumours. The scintigraphic image showed no correlation with the histopathological type of the tumour or with the abundance of oestrogen/progesterone receptors on the tumour. Two patients with a massive tumour infiltration of the lymph nodes had a distinct positive SRS of the ipsilateral axilla. In one patient with three nodal metastases the scintigraphic image of the axilla was weak but visible. Four other patients with a negative axillary scintigraphy had 1–2 lymph node metastases. The Ti/B ratios for the breast tumours varied between four and 33 and were not different from Ti/Br ratios. In lymph node metastases the Ti/B ratios were higher (10–41). Intraoperative detector measurements showed a significant difference between the breast tumour and normal tissue in 2/8 patients in situ. Similar measurements on excised tissues (ex vivo) showed a significant difference in 6/8 patients. Two patients with lymph node metastases exhibited a significantly increased uptake ex vivo by detector measurements, but in only one of them in situ. All tumour biopsies expressed the presence of sstr1, 3, 4 and 5, but not of sstr2 at northern analysis. On the other hand, sstr2 was detected in all tumours by RPA and immunocytochemistry. Preoperative SRS visualised primary breast cancer lesions in all 12 patients. SRS could also demonstrate extensive axillary tumour infiltration. Intraoperative use of the scintillation detector could not exclude axillary metastases in situ. The low Ti/B values of both primary tumours and metastases indicate limitations of the radiopharmaceutical used.
Similar content being viewed by others
References
Ain KB, Taylor KD: Somatostatin analogs affect prolifera-tion of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 78(5): 1097–1102, 1994
Weckbecker G, Liu R, Tolcsvai L, Bruns C: Antiproliferative effects of the somatostatin analogue octreotide (SMS 201–99575-1 human breast cancer cells in vivo and in vitro. Cancer Res 52(18): 4973-4978, 1992
Weckbecker G, Raulf F, Bodmer D, Bruns C: Indirect antipro-liferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice. Yale J Biol Med 70(5–6): 549-554, 1997
Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S: Cloning and functional characterization of a family of hu-man and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 89(1): 251–255, 1992
Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell GI, Seino S: Somatostatin receptors, an expanding gene family: cloning and functional characteriz-ation of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 6(12): 2136–2142, 1992.
Rohrer L, Raulf F, Bruns C, Buettner R, Hofstaedter F, Schule R: Cloning and characterization of a fourth human soma-tostatin receptor. Proc Natl Acad Sci USA 90(9): 4196–4200, 1993
Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, Imura H, Seino S: Cloning, func-tional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 195(2): 844–852, 1993
Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D, Lubbert H: Molecular pharmacology of somatostatin-receptor subtypes. Ann NY Acad Sci 733: 138–146, 1994
Pollak MN, Polychronakos C, Guyda H: Somatostatin ana-logue SMS 201–995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 9(4): 889-891, 1989
Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, Barrie R: Somatostatin analogs: an-giogenesis inhibitors with novel mechanisms of action. Invest New Drugs 15(1): 77–86, 1997
Ahlman H, Tisell LE, Wangberg B, Nilsson O, Forssell-Aronsson E, Fjalling M: Somatostatin receptor imaging in patients with neuroendocrine tumors: preoperative and post-operative scintigraphy and intraoperative use of a scintillation detector. Semin Oncol 21(5 suppl 13): 21–28, 1994
Ahlman H, Wangberg B, Tisell LE, Nilsson O, Fjalling M, Forssell-Aronsson E: Clinical efficacy of octreotide scinti-graphy in patients with midgut carcinoid tumours and evalu-ation of intraoperative scintillation detection. Br J Surg 81(8): 1144–1149, 1994
Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C: Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 37(6): 912–916, 1996
Tisell LE, Ahlman H, Wangberg B, Hansson G, Molne J, Nilsson O, Lindstedt G, Fjalling M, Forssell-Aronsson E: Somatostatin receptor scintigraphy in medullary thyroid car-cinoma. Br J Surg 84(4): 543–547, 1997
Kölby L, Wängberg B, Ahlman H, Tisell LE, Fjälling M, Forssell-Aronsson E, Nilsson O: Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J Surg 22(7): 679–683, 1998
Wängberg B, Forssell-Aronsson E, Tisell LE, Nilsson O, Fjälling M, Ahlman H: Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide. Br J Cancer 73(6): 770–775, 1996
Adams S, Baum RP, Hertel A, Wenisch HJ, Staib-Sebler E, Herrmann G, Encke A, Hor G: Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med 39(7): 1155–1160, 1998
Fjälling M, Andersson P, Forssell-Aronsson E, Gretarsdottir J, Johansson V, Tisell LE, Wängberg B, Nilsson O, Berg G, Michanek A: Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J Nucl Med 37(9): 1519–1521, 1996
Setyono-Han B, Henkelman MS, Foekens JA, Klijn GM: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47(6): 1566–1570, 1987
Sharma K, Srikant CB: Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 76(2): 259–266, 1998
Bontenbal M, Foekens JA, Lamberts SW, de Jong FH, van Putten WL, Braun HJ, Burghouts JT, van der Linden GH, Klijn JG: Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast can-cer: a randomized study with long-term follow-up. Br J Cancer 77(1): 115–122, 1998
van Eijck CH, Krenning EP, Bootsma A, Oei HY, van Pel R, Lindemans J, Jeekel J, Reubi JC, Lamberts SW: Somatostatin-receptor scintigraphy in primary breast cancer [see com-ments]. Lancet 343(8898): 640–643, 1994
Chomczynski P, Sacchi N: Single-step method of RNA isol-ation by acid guanidinium thiocyanate-phenol-chloroform ex-traction. AnalBiochem 162(1): 156–159, 1987
Forssell-Aronsson E, Nilsson O, Benjegård SA, Bernhardt P: 111 In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 41(4): 636–642, 2000
Nilsson O, Kölby L, Wängberg B, Wigander A, Billig H, William-Olsson L, Fjälling M, Forssell-Aronsson E, Ahlman H: Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 77(4): 632–637, 1998
Reubi JC, Waser B, Foekens JA, Klijn JG, Lamberts SW, Laissue J: Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer 46(3): 416–420, 1990
Prevost G, Hosford D, Thomas F: Receptors for somatostatin and somatostatin analogues in human breast tumors. Ann N Y Acad Sci 733: 147–154, 1994
Bajc M, Ingvar C, Palmer J: Dynamic indium-111-pentetreo-tide scintigraphy in breast cancer. J Nucl Med 37(4): 622–626, 1996
Reubi JC, Schaer JC, Waser B, Mengod G: Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54(13): 3455–3459, 1994
Reubi JC, Schaer JC, Laissue JA, Waser B: Somatostatin re-ceptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 45 (8 suppl 1): 39–41, 1996
John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherubl H, Boese-Landgraf J, Neuhaus P, Ziske C, Molling K: Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 38(1): 33–39, 1996
Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S: Expres-sion of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 80(10): 2974–2979, 1995
Evans AA, Crook T, Laws SA, Gough AC, Royle GT, Primrose JN: Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer 75(6): 798–803, 1997
Ain KB, Taylor KD, Tofiq S, Venkataraman G: Somatostatin receptor subtype expression in human thyroid and thyroid car-cinoma cell lines. J Clin Endocrinol Metab 82(6): 1857–1862, 1997
Forssell-Aronsson E, Fjalling M, Nilsson O, Tisell LE, Wangberg B, Ahlman H: Indium-111 activity concentra-.Somatostatin receptors and breast cancer 111 tion in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J Nucl Med 36(1): 7–12, 1995
Xu Y, Song J, Berelowitz M, Bruno JF: Estrogen regulates so-matostatin receptor subtype 2 messenger ribonucleic acid ex-pression in human breast cancer cells. Endocrinology 137(12): 5634–5640, 1996
Mansi L, Rambaldi PF, Procaccini E, Gregoio FD, Laprovit-era A, Pecori B, Vecchio WD: Scintimammography with technetium-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases. Eur J Nucl Med 23(8): 932–939, 1996
Vural G, Unlu M, Atasever T, Ozur I, Ozdemir A, Gokcora N: Comparison of indium-111 octreotide and thallium-201 scintigraphy in patients mammographically suspected of hav-ing breast cancer: preliminary results. Eur J Nucl Med 24(3): 312–315, 1997
Chiti A, Agresti R, Maffioli LS, Tomasic G, Savelli G, Crippa F, Pilotti S, Greco M, Bombardieri E: Breast cancer staging using technetium-99m sestamibi and indium-111 pentet-reotide single-photon emission tomography. Eur J Nucl Med 24(2): 192–196, 1997
Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, Costa A, de Cicco C, Geraghty JG, Luini A: Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes [see comments]. Lancet 349(9069): 1864–1867, 1997
Zurrida S, Galimberti V, Orvieto E, Robertson C, Ballardini B, Cremonesi M, De Cicco C, Luini A: Radioguided sentinel node biopsy to avoid axillary dissection in breast cancer. Ann Surg Oncol 7(1): 28–31, 2000
Ahlman H, Tisell LE, Wangberg B, Nilsson O, Fjalling M, Forssell-Aronsson E: Somatostatin receptors on neuroendo-crine tumors-a way to intraoperative diagnosis and localiza-tion. Yale J Biol Med 67(3–4): 215-221, 1994
Pollak M: Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Digestion 57(suppl 1): 29–33, 1996
Slooter GD, Breeman WA, Marquet RL, Krenning EP, van Eijck CH: Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer 81(5): 767–771, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Skånberg, J., Ahlman, H., Benjegård, SA. et al. Indium-111-octreotide Scintigraphy, Intraoperative Gamma-detector Localisation and Somatostatin Receptor Expression in Primary Human Breast Cancer. Breast Cancer Res Treat 74, 101–111 (2002). https://doi.org/10.1023/A:1016120529858
Issue Date:
DOI: https://doi.org/10.1023/A:1016120529858